Jazz Pharma Reports Pro Forma Epidiolex Sales Grew 32% to $156 Million in Q2

As Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals says: “We have now executed four of five planned product launches since the beginning of 2020 and look forward to our anticipated launch of Xywav in idiopathic hypersomnia later this year, a critical step forward for these underserved patients. With 41% of our second quarter net product sales from recently launched or acquired products, we are well on track to meet our revenue diversification targets while driving significant shareholder value.”